Plausibly Exogenous [1434] - Market Exclusivity (01/04/2024)
LHS Variable
Drug innovation
RHS Variable
Market exclusivity
Source of Exogenous Variation
The Generating Antibiotic Incentives Now (GAIN) Act, first introduced in Congress in 2010 and enacted in 2012, extended the nonpatent exclusivity period for certain “Qualifying Infectious Disease Products” (QIDPs) by an additional 5 years, a significant extension given the baseline exclusivity of 5 years for NCEs
- Kong and Zhao (2023), “Market Exclusivity and Innovation: Evidence From Antibiotics”